Skip to main content
. 2003 Jun;55(6):518–525. doi: 10.1046/j.1365-2125.2003.01796.x

Figure 2.

Figure 2

Mean ± SD visual analogue scale (VAS) alertness profiles for the moxonidine sustained release (SR) (•) and placebo (○) treatment groups during study day 8 and day 29. Each profile represents a different study day; measurements were performed from predose (first two data points) until 10 h postdose.